Hypothalamic Obesity - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The hypothalamic obesity market size was valued at USD 0.89 billion in 2025 and is estimated to grow from USD 0.97 billion in 2026 to reach USD 1.51 billion by 2031, at a CAGR of 9.23% during the forecast period (2026-2031). This report is segmented by Etiology (Craniopharyngioma-Associated, Other Acquired), Treatment Type (Disease-Specific Pharmacological, Hormone Replacement, Others), Patient Group (Pediatric, Adolescent, Adult), Care Setting (Hospitals, Specialty Centers, Home-Based Care), and Geography (North America, Europe, Asia-Pacific, MEA, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Hypothalamic Obesity Market Trends and Insights

Increasing Recognition of Hypothalamic Obesity as a Distinct Disease

The hypothalamic obesity market is supported by the growing separation of acquired hypothalamic obesity from general obesity and other MC4R pathway conditions. An international expert guidance document published in 2025 established diagnostic criteria that included a BMI increase of at least 5% in adults within 12 months after hypothalamic damage. The same guidance used an increase of at least 1 SDS for pediatric patients within that period. A 2025 expert paper also reported inconsistent use of ICD-10-CM code E88.82 across health systems and called for a dedicated code for acquired disease. A clearer disease label can make trial recruitment, payer review, and real-world evidence collection more consistent. It can also help providers distinguish patients who require specialized neuroendocrine management from people receiving standard obesity care.

Expansion of Disease-Specific MC4R Therapy

The hypothalamic obesity market gained a new treatment pathway when IMCIVREE received U.S. approval in March 2026 for acquired hypothalamic obesity. The European Commission authorized the therapy on May 1, 2026, and Japan authorized it on August 24, 2026. IMCIVREE generated USD 60.10 million in global net sales during Q1 2026. Rhythm in-licensed oral MC4R agonist bivamelagon in January 2024 for USD 100 million upfront and plans a pivotal Phase 3 trial for acquired hypothalamic obesity by the end of 2026. The company also reported preliminary Phase 2 data for once-weekly injectable RM-718 in August 2026. Oral and once-weekly options may address daily injection burden and tolerability concerns as the treatment base develops.

Limited Disease Recognition and Diagnostic Coding

The hypothalamic obesity market remains constrained because acquired hypothalamic obesity lacks a dedicated ICD-10-CM diagnosis code. In May 2026, the Obesity Action Coalition stated that the absence of a distinct code can prevent accurate communication of the diagnosis and delay access to evidence-based care. Providers often combine endocrine-disorder and general-obesity codes in their documentation. This creates inconsistency during prior authorization for therapies with novel mechanisms and high costs. Incomplete coding also limits claims-based measurement of prevalence and outcomes. Lower visibility in claims data can weaken payer incentives to create clear coverage pathways. These issues can slow the conversion of clinical demand into sustained treatment access.

Other drivers and restraints analyzed in the detailed report include:

• Rising Survivorship After Pediatric Brain Tumor Treatment
• Growth of Multidisciplinary Rare-Disease Care
• High Cost and Reimbursement Complexity of Specialty Therapies

Segment Analysis

Craniopharyngioma-associated hypothalamic obesity accounted for 42.80% of the hypothalamic obesity market size by etiology in 2025. It is the most extensively studied cause of hypothalamic injury and represents most patients in pivotal clinical research. A 2025 review reported that hypothalamic obesity affected 40%-50% of people with craniopharyngioma. The degree of hypothalamic involvement before surgery remained a principal factor in postsurgical weight outcomes.. This creates a strong case for early intervention rather than observation after treatment. Treatment-induced and other CNS tumor-associated diseases form important secondary groups. Radiation-related hypothalamic damage can add to demand as cancer survival improves. Other acquired cases, including traumatic brain injury and non-tumor microinjuries, remain less well served.

Congenital and genetic hypothalamic obesity is forecast to expand at a 10.80% CAGR through 2031. This group includes conditions such as Prader-Willi syndrome and POMC or LEPR deficiency obesity. FDA approvals in 2025 and 2026 created commercial pathways for VYKAT XR in Prader-Willi syndrome hyperphagia and IMCIVREE in several genetic forms of severe obesity. More precise genetic diagnosis can identify patients who may qualify for targeted treatment. Testing quality is important because payers may seek diagnostic certainty before authorizing high-cost therapies. The segment combines an identifiable genetic cause with a growing number of targeted options. It therefore has a different access pathway from acquired disease caused by tumors or treatment

Nutritional and lifestyle management held 36.50% of the treatment mix in 2025. It remained the standard approach when approved disease-specific drugs were unavailable. Disease-specific pharmacological therapy is forecast to grow at an 18.40% CAGR from 2026 to 2031. IMCIVREE created this category after its March 2026 approval for acquired hypothalamic obesity. Growth from a very limited commercial base helps explain the high projected rate. A 2025 observational study reported a median weight loss of 16% after 24 months of semaglutide treatment in craniopharyngioma patients. The study also reported lower emotional-eating scores and improved quality of life. GLP-1 receptor agonists can therefore provide an off-label option while disease-specific therapy becomes more available.

Nutritional support will continue to complement pharmacotherapy rather than disappear from care pathways. Hormone replacement therapy, metabolic and bariatric surgery, and other supportive therapies remain smaller but steady treatment options. Bariatric surgery can provide durable weight loss for selected patients. Complex endocrine conditions can increase perioperative risk and restrict their broader use. A French multicenter real-world study included 116 adults across 16 obesity centers. It reported mean weight loss of 6.80% with semaglutide in patients without diabetes. This evidence supports a more formal role for GLP-1 treatment as supportive care. Pharmacological options may also make patients and physicians more comfortable with active obesity management after hypothalamic damage.

Complete Report Scope:

• By Etiology
  • Craniopharyngioma-Associated Hypothalamic Obesity
  • Other CNS Tumor-Associated Hypothalamic Obesity
  • Treatment-Induced Hypothalamic Obesity
  • Congenital and Genetic Hypothalamic Obesity
  • Other Acquired Hypothalamic Obesity
• By Treatment Type
  • Disease-Specific Pharmacological Therapy
  • Hormone Replacement Therapy
  • Nutritional and Lifestyle Management
  • Metabolic and Bariatric Surgery
  • Other Supportive Therapies
• By Patient Group
  • Pediatric Patients
  • Adolescent and Young Adult Patients
  • Adult Patients
  • Patients with Complex Endocrine Comorbidities
• By Care Setting
  • Tertiary Care Hospitals
  • Endocrinology Specialty Centers
  • Obesity and Metabolic Clinics
  • Home-Based Care and Remote Monitoring
  • Academic and Research Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.30% of the hypothalamic obesity market share in 2025. The region combines a large rare-disease drug market with the FDA approval of IMCIVREE in March 2026. Rhythm estimated that 10,000 people in the United States have acquired hypothalamic obesity. The TRANSCEND trial enrolled 142 patients across 29 sites and 6 countries. The difference between identified patients and trial participation supports continued attention to diagnosis and referral. Canada and Mexico share some similar clinical practices. Their reimbursement frameworks can be more restrictive for novel biologics. A dedicated U.S. diagnosis code could reduce documentation barriers during prior authorization.

Europe has major patient registries and clinical research infrastructure in Germany, France, and the United Kingdom. The European Commission authorized IMCIVREE for acquired hypothalamic obesity on May 1, 2026. Each country has a separate health technology assessment pathway. These processes will determine the speed and breadth of reimbursed access. Germany’s statutory insurance system, France’s early-access approach, and the United Kingdom’s Innovative Medicines Fund can support rare-disease treatment access. They can also limit uptake when evidence or cost-effectiveness requirements are unresolved. Spain and Italy are secondary priority countries. Other European countries maintain specialist academic centers that contribute to clinical research.

Asia-Pacific is forecast to grow at a 10.20% CAGR from 2026 to 2031. Japan authorized IMCIVREE on August 24, 2026, following orphan drug designation in March 2025. The TRANSCEND trial included 12 patients in Japan. Those data informed the regulatory submission and may support pricing discussions under Japan’s National Health Insurance framework. South Korea has an interest through LG Chem Life Sciences and bivamelagon’s development arrangement with Rhythm. A Chinese study reported that 64.30% of treated patients achieved more than 5% weight loss at 3 months and 90% did so at 6 months after craniopharyngioma surgery. Middle East and Africa remains at an earlier stage of rare-disease recognition and specialist capacity. South America shows growing advocacy activity, but budget constraints can limit reimbursement during the forecast period.

List of Companies Covered in this Report:

• Ionis Pharmaceuticals
• Amgen
• AstraZeneca
• Blueprint Genetics
• Boehringer Ingelheim
• Camurus AB
• Currax Pharmaceuticals
• Eli Lilly and Company
• GeneDx
• LG Chem
• Merck
• Neurocrine Biosciences
• Novartis
• Novo Nordisk
• Pfizer
• Rhythm Pharmaceuticals, Inc.
• Roche
• Saniona
• Soleno Therapeutics, Inc.
• VIVUS LLC
• Ipsen
• Zealand Pharma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support